Revvity's Sphere Fluidics Expands Global Operations to Meet Single-Cell Analysis Demand
- Sphere Fluidics expands global operations to enhance customer access to its Cyto-Mine Chroma platform and single-cell solutions.
- Dr. Erroll Rueckert leads North America sales, focusing on localized engagement to meet growing market demand.
- The company strengthens its team and services in Europe and Asia-Pacific to address specific regional customer needs.
Sphere Fluidics Expands Global Commercial Operations to Meet Growing Demand
Sphere Fluidics, a leader in droplet-based microfluidics solutions for single-cell functional profiling, embarks on a significant expansion of its global commercial operations. This strategic move focuses on enhancing customer access to its innovative products, particularly the newly launched Cyto-Mine Chroma platform. The company establishes a direct sales and support channel in North America, recognizing the need for localized engagement in a rapidly growing market. Dr. Erroll Rueckert is appointed as the North America Commercial Director and is charged with spearheading this initiative. His extensive experience in single-cell analysis and genomics, garnered through previous roles at NanoString and Lightcast Discovery, positions him well to build a robust sales team and effectively address customer needs.
In Europe, Sphere Fluidics prioritizes a similar shift towards direct sales in key markets, specifically Germany and France, where demand for single-cell analysis solutions is surging. Dr. Graeme Daniels, the VP of Commercial for EMEA, leads this transition, leveraging his background in BioPharma to navigate the unique challenges and opportunities presented in these critical regions. His experience at IsoPlexis and Horizon Discovery equips him with the insights necessary to adapt Sphere Fluidics' sales strategies to meet the growing expectations of European customers. This localized approach aims to enhance customer relationships and ensure that clients receive tailored support for their specific needs.
In the Asia-Pacific region, Sphere Fluidics appoints Dr. Jay Manikandan as VP of Commercial to drive growth and oversee distributor networks from Singapore. Drawing on his experience at 10x Genomics and Bruker Spatial Biology, Manikandan aims to capitalize on the burgeoning demand for functional profiling solutions in this dynamic market. Alongside him, Jay Gerlach’s appointment as VP of Global Marketing is set to strengthen Sphere's outreach and brand presence worldwide. CEO Dale Levitzke highlights that these strategic appointments and operational expansions are critical to scaling the company’s capabilities and ensuring proactive responses to evolving market demands.
In addition to the establishment of direct sales channels, Sphere Fluidics is committed to recruiting top-tier sales talent. This focus is essential for maintaining a competitive edge in the increasingly sophisticated landscape of single-cell analysis. By building a capable team and implementing effective processes, Sphere Fluidics positions itself to meet the diverse needs of its global clientele.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

